Understanding the racial and ethnic differences in cost and mortality among advanced stage prostate cancer patients (STROBE)

Medicine (United States)

Volumn 94, Issue 32, 2015, Pages

  Chhatre, Sumedha ^a   Malkowicz, Stanley Bruce ^b   Schwartz, J Sanford ^a   Jayadevappa, Ravishankar ^a,b,c   Burke, Harry ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; AGED; ARTICLE; ASIAN; BLACK PERSON; CANCER MORTALITY; CANCER PATIENT; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; ETHNIC GROUP; HEALTH CARE COST; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; AFRICAN AMERICAN; AGE; CANCER STAGING; COST; ECONOMICS; ETHNOLOGY; MEDICARE; MORTALITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; COSTS AND COST ANALYSIS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HISPANIC AMERICANS; HUMANS; MALE; MEDICARE; NEOPLASM STAGING; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84942431044     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001353     Document Type: Article

References (27)

1. Siegel R, Ma J, Zoy Z, et al. Cancer Statistics 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Instit. 2008; 100: 630-641.
3. Fung C, Dale W, Mohile SG. Prostate cancer in the elderly patient. J Clin Oncol. 2014; 55: 1531-1539.
4. Gross CP, Smith BD, Wolf E, et al. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. 2008; 112: 900-908.
5. Polednak AP Prostate cancer treatment in black and white men: the need to consider both stage at diagnosis and socioeconomic status. J Natl Med Assoc. 1998; 90: 101-104.
6. Smedley BD, Stith AY, Nelson AR (Editors). Unequal Treatment-Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: The National Academic Press; 2002.
7. Yannurajalingam S, Atkinson B, Masterson J, et al. The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients. J Palliat Med. 2012; 15: 20-24.
8. Penson DF, Chan JM. Urologic Diseases in America. Washington, DC2007. US Government Printing Office, 2007; NIH Pub. No. 07-5512 [pp. 71-123].
9. Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007; 109: 518-527.
10. Warren JL, Klabunder CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research application and generalizability to the United States elderly population. Med Care. 2002; 40 (supp) IV-3-18.
11. Adamo MB, Johnson CH, Ruhl JL, Dickie Le. 2013 SEER Program Coding and Staging Manual. Bethesda, MD: National Cancer Institute; 2013.
12. Brown ML, Riley GF, Schussler N, et al. Estimating care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002; 40 (suppl) IV-104-117.
13. Riley GF, Potosky AL, Lubitz JD, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage and diagnosis. Med Care. 1995; 33: 828-841.
14. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008; 100: 888-897.
15. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
17. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46: 1075-1079.
18. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
19. Zhou XH, Melfi CA, Hui SL. Methods of comparison of cost data. Ann Intern Med. 1997; 127: 752-756.
20. Green WH Econometric Analysis. Upper Saddle River, NJ: Prentice-Hall; 2007.
21. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001; 20: 461-494.
22. Allison PD Logistic Regression Using the SAS System: Theory and Application Cairy, NC: SAS Institute Inc; 1999.
23. Marlow NM, Halpern MT, Pavluck AI, et al. Disparities associated with advanced prostate cancer stage at diagnosis. J Health Care Poor Underserved. 2010; 21: 112-131.
24. Hu Yue-Yung, Kwok AC, Jiang W, et al. High cost imaging in elderly patients with stage IV cancer. J Natl Cancer Inst. 2012; 104: 1164-1172.
25. Committee on quality of health care in America-Institute of Medicine. Cross the Quality Chasm: a new health care system for the 21st century. Washington, DC, 2005.
26. Payne H, Bahl A, Mason M, et al. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJUI. 2012; 110: 658-667.
27. Polednak AP Black-white differences in survival from late-stage prostate cancer. Ethn Dis. 2003; 13: 220-225.